Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

Metroplex Clinical Research Center, Dallas, Texas, USA.
Annals of the rheumatic diseases (Impact Factor: 10.38). 06/2010; 69(6):1158-61. DOI: 10.1136/ard.2009.119222
Source: PubMed


Rituximab inhibited structural damage at 1 year in patients with rheumatoid arthritis (RA) who had had a previous inadequate response to tumour necrosis factor (TNF) inhibitors.
To assess structural damage progression through 2 years.
Intention-to-treat patients with one post-baseline radiograph (rituximab n=281; placebo n=187) received background methotrexate (MTX) and were randomised to rituximab (2 x 1000 mg infusions, 2 weeks apart) or placebo; patients were eligible for rituximab re-treatment every 6 months. By week 104, 82% of the placebo population had received > or = 1 dose of rituximab. Radiographic end points included the change in total Sharp score (TSS), erosion and joint space narrowing scores at week 104.
At week 104, significantly lower changes in TSS (1.14 vs 2.81; p<0.0001), erosion score (0.72 vs 1.80; p<0.0001) and joint space narrowing scores (0.42 vs 1.00; p<0.0009) were observed with rituximab plus MTX vs placebo plus MTX. Within the rituximab group, 87% who had no progression of joint damage at 1 year remained non-progressive at 2 years.
Rituximab plus MTX demonstrated significant and sustained effects on joint damage progression in patients with RA and a previously inadequate response to TNF inhibitors.

Download full-text


Available from: Paul Emery,
  • Source
    • "As erosion occurs early in the course of the disease,43 prevention of radiological progression with the use of a higher dose of rituximab seems to be logical in patients with early RA. In patients who are refractory to the anti-TNF biologics, a lower dose of rituximab (two doses of 500 mg) has not been tested for radiological progression, whereas efficacy in slowing radiological damage has been shown with the higher dosing regimen (two doses of 1,000 mg).33 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule expressed on the surface of B cells. It was first used in the treatment of non-Hodgkin's lymphoma and later approved for the treatment of rheumatoid arthritis (RA) that does not respond adequately to disease-modifying antirheumatic drugs, including the anti-tumor-necrosis-factor (TNF) biologics. Sustained efficacy in RA can be achieved by repeated courses of rituximab. However, the optimal dose and retreatment schedule of rituximab in RA remains to be established. Seropositivity, complete B cell depletion shortly after treatment, and previous failure to no more than one anti-TNF agent are three factors associated with greater clinical benefits to rituximab. Infusion reaction to the first dose of rituximab occurs in approximately 25% of RA patients, and the incidence reduces with subsequent exposure. Immunogenicity to the chimeric compound occurs in 11% of RA patients, but this does not correlate with its efficacy in B cell depletion. Extended observation of randomized controlled trials in RA does not reveal a significant increase in the incidence of serious infections related to rituximab compared to placebo groups, and the infection rate remains static over time. Repeated treatment with rituximab is associated with hypogammaglobulinemia, which may increase the risk of serious, but rarely opportunistic, infections. Reactivation of occult hepatitis B infection has been reported in RA patients receiving rituximab, but no increase in the incidence of tuberculosis was observed. Screening for baseline serum immunoglobulin G level and hepatitis B status (including occult infection) is important, especially in Asian countries where hepatitis B infection is prevalent. The rare but fatal progressive multifocal leukoencephalopathy linked to the use of rituximab has to be noted. Postmarketing surveillance and registry data, particularly in Asia, are necessary to establish the long-term efficacy and safety of rituximab in the treatment of RA.
    Drug Design, Development and Therapy 12/2013; 8:87-100. DOI:10.2147/DDDT.S41645 · 3.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: For the first time tunnel junctions with a ferroelectric barrier (FTJ) have been prepared and a bi-stable and highly reproducible hysteresis in the I-V curve and the bias dependence of the dynamic conductance has been measured. This behavior will be discussed in the framework of a possible new effect based on the interplay between the polarization state in the barrier and direct electron tunneling through the barrier.
    Device Research Conference, 2002. 60th DRC. Conference Digest; 02/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent so-called very short-scan fan-beam reconstruction algorithms make it possible to reconstruct objects within the convex hull of the source path provided that the object is completely contained within the filed of view in all projections. In this work, we extend this result to the truncated cone-beam projection scenario that is typical of mobile C-arms in surgery under the assumption that a prior computed tomography scan is available and that the anatomy has only changed due to surgery within the convex hull of the source path. Practical algorithms and simulation results are given.
    Signals, Systems and Computers, 2003. Conference Record of the Thirty-Seventh Asilomar Conference on; 12/2003
Show more